Two Sigma Investments, LP Satsuma Pharmaceuticals, Inc. Transaction History

Two Sigma Investments, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.7 - $1.07 $3,628 - $5,545	5,183 Added 1.78%	297,129 $207,000
Q4 2022 Feb 14, 2023	BUY	$0.61 - $5.06 $171,664 - $1.42 Million	281,417 Added 2672.78%	291,946 $262,000
Q3 2022 Nov 14, 2022	SELL	$4.19 - $7.95 $13,156 - $24,963	-3,140 Reduced 22.97%	10,529 $63,000
Q2 2022 Aug 15, 2022	SELL	$2.59 - $4.3 $96,878 - $160,841	-37,405 Reduced 73.24%	13,669 $57,000
Q1 2022 May 16, 2022	SELL	$3.78 - $5.32 $180,959 - $254,684	-47,873 Reduced 48.38%	51,074 $194,000
Q4 2021 Feb 14, 2022	SELL	$4.15 - $6.24 $145,515 - $218,799	-35,064 Reduced 26.17%	98,947 $445,000
Q3 2021 Nov 15, 2021	SELL	$4.54 - $7.17 $756,763 - $1.2 Million	-166,688 Reduced 55.43%	134,011 $624,000
Q2 2021 Aug 16, 2021	BUY	$4.8 - $7.25 $453,403 - $684,827	94,459 Added 45.8%	300,699 $2.12 Million
Q1 2021 May 17, 2021	BUY	$4.57 - $7.18 $617,544 - $970,233	135,130 Added 190.03%	206,240 $1.22 Million
Q4 2020 Feb 16, 2021	SELL	$3.56 - $5.09 $663,085 - $948,063	-186,260 Reduced 72.37%	71,110 $328,000
Q3 2020 Nov 16, 2020	BUY	$3.85 - $28.47 $990,874 - $7.33 Million	257,370 New	257,370 $1 Million

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.